S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

$5.40
0.00 (0.00%)
(As of 04/17/2024 ET)
Today's Range
$5.27
$5.77
50-Day Range
$4.81
$6.53
52-Week Range
$1.93
$6.79
Volume
299,196 shs
Average Volume
320,220 shs
Market Capitalization
$322.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67

Lyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
134.4% Upside
$12.67 Price Target
Short Interest
Healthy
0.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.04) to ($1.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.62 out of 5 stars

Medical Sector

656th out of 913 stocks

Surgical & Medical Instruments Industry

63rd out of 89 stocks

LYRA stock logo

About Lyra Therapeutics Stock (NASDAQ:LYRA)

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

LYRA Stock Price History

LYRA Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
LYRA Jul 2024 2.500 call
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
LYRA Jul 2024 7.500 call
LYRA Apr 2024 7.500 put
LYRA May 2024 7.500 call
15 Unhappiest States in the US
Lyra Therapeutics Insider Ups Holding By 11% During Year
See More Headlines
Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/17/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LYRA
Fax
N/A
Employees
88
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$15.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+134.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-62,680,000.00
Net Margins
-4,023.11%
Pretax Margin
-4,019.32%

Debt

Sales & Book Value

Annual Sales
$1.56 million
Book Value
$1.56 per share

Miscellaneous

Free Float
49,336,000
Market Cap
$323.19 million
Optionable
Optionable
Beta
0.23
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Harlan W. Waksal M.D. (Age 71)
    Executive Chairman
    Comp: $210.06k
  • Dr. Maria Palasis Ph.D. (Age 59)
    CEO, President & Director
    Comp: $942.7k
  • Dr. John E. Bishop Ph.D. (Age 62)
    Chief Technology Officer
    Comp: $662.9k
  • Dr. Carmichael S. Roberts Jr. (Age 56)
    Ph.D., Co-Founder
  • Mr. Jason Cavalier (Age 51)
    CFO, Treasurer & Secretary
    Comp: $464.11k
  • Mr. Ray Knox
    Vice President of Operations
  • Ms. Ellen Cavaleri
    Senior Vice President of Investor Relations & Communications
  • Mr. Ronan P. O'Brien J.D. (Age 51)
    Chief Legal Officer
  • Ms. Corinne Noyes (Age 56)
    Senior Vice President of Commercial Strategy & Market Development
    Comp: $426.73k
  • Ms. Vineeta Belanger Ph.D.
    Senior Vice President of Clinical Affairs

LYRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Lyra Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LYRA shares.
View LYRA analyst ratings
or view top-rated stocks.

What is Lyra Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued twelve-month target prices for Lyra Therapeutics' shares. Their LYRA share price targets range from $11.00 to $15.00. On average, they anticipate the company's stock price to reach $12.67 in the next year. This suggests a possible upside of 134.4% from the stock's current price.
View analysts price targets for LYRA
or view top-rated stocks among Wall Street analysts.

How have LYRA shares performed in 2024?

Lyra Therapeutics' stock was trading at $5.24 on January 1st, 2024. Since then, LYRA stock has increased by 3.1% and is now trading at $5.4050.
View the best growth stocks for 2024 here
.

When is Lyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LYRA earnings forecast
.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. The firm earned $0.15 million during the quarter, compared to analysts' expectations of $0.52 million. Lyra Therapeutics had a negative net margin of 4,023.11% and a negative trailing twelve-month return on equity of 72.62%.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an initial public offering (IPO) on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LYRA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners